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ABSTRACT
Background and Objectives: Lymph node metastases
are the most important prognostic factor in patients with
esophageal cancer. Histologic examination misses
micrometastases in up to 20% of lymph nodes evaluated.
In addition, non-invasive imaging modalities are not sen-
sitive enough to detect small lymph nodes metastases.
The objective of this study was to investigate the use of
reverse transcriptase-polymerase chain reaction (RT-PCR)
of messenger RNA (mRNA) for carcinoembryonic antigen
(CEA) to increase the detection of micrometastases in
lymph nodes from patients with esophageal cancer.
Methods: RT-PCR of CEA mRNA was performed in
lymph nodes from patients with malignant and benign
esophageal disease. Each specimen was examined
histopathologically and by RT-PCR and the results were
compared.
Results: Metastases were present in 29 of 60 (48%) lymph
nodes sample by minimally invasive staging from 13
patients with esophageal cancer when examined
histopathologically. RT-PCR identified nodal metastases in
46 of these 60 (77%) samples. RT-PCR detected CEA
mRNA in all 29 histologically positive samples and in 17
histologically negative lymph nodes. All lymph nodes
from patients with benign disease (n=15) were negative
both histopathologically and by RT-PCR. The stage of two
patients was reclassified based on the RT-PCR results,
which identified lymph node spread undetected
histopathologically. Both of these patients developed
recurrent disease after resection of the primary tumor.
Conclusions: RT-PCR is more sensitive than histologic
examination in the detection of lymph node metastases in
esophageal cancer and can lead to diagnosis of a more
advanced stage in some patients. The combination of
minimally invasive surgical techniques in combination
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with new molecular diagnostic techniques may improve
our ability to stage cancer patients.
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INTRODUCTION
The incidence of adenocarcinoma of the esophagus is
rising at an alarming rate.
1 The prognosis is poor, with
a five year survival of 5-10%. Randomized studies indi-
cate that multimodality regimens have not been uni-
formly successful in improving survival compared to sur-
gery alone.
2 One problem in the design of these trials is
that pre- and post- treatment staging was performed by
conventional imaging which has been shown to be inac-
curate in up to 40% of patients with esophageal cancer
when compared to minimally invasive surgical staging.
3,
4
Even when surgical staging is performed, lymph node
assessment may be inaccurate due to sampling errors at
the time of nodal dissection.
3,
4 In addition, micrometas-
tases may escape detection by routine histopathologic
methods in up to 20% of cases.
5 The application of
recent advances in molecular biology may facilitate the
detection of micrometases in lymph nodes, thereby lim-
iting the requirement for extensive surgical sampling,
and increasing the accuracy of staging.
Carcinoembryonic antigen (CEA) is a recognized tumor
marker that is expressed in a variety of malignancies.
CEA has been most extensively studied as a serum mark-
er of recurrence of colorectal cancer after surgical resec-
tion.
6 The complete gene for CEA has recently been
cloned and complete sequence information is available.
7
Recently, a CEA-specific nested PCR assay to detect CEA
producing cells from bone marrow aspirates has been
described.
8 In a preliminary study, this assay was modi-
fied to detect micrometastases in lymph nodes in a small
number of patients with esophageal, gastric, colorectal,
and breast carcinoma.
9
JSLS (1998)2:331-336 331Detection of Occult Lymph Node Metastases in Esophageal Cancer by Minimally Invasive Staging Combined with Molecular Diagnostic
Techniques, Kassis ES, et al.
The purpose of this investigation was to investigate the
utility of RT-PCR for detecting micrometastases in histo-
logically negative lymph nodes in patients with
esophageal cancer. The ability to detect micrometastases
by utilizing minimally invasive surgical techniques would
provide concrete pathological evidence of lymph node
status, without subjecting patients to unnecessary surgi-
cal intervention. Minimally invasive surgical techniques
have been shown to be cost-effective as well as to
improve patient outcomes, and in the application of
lymph node sampling for staging purposes, this modali-
ty would ultimately serve as a "gold standard."
MATERIALS AND METHODS
RNA Extraction
Total cellular RNA was extracted from all samples by a
modified guanidinium thiocyanate extraction method
1
0
using a RNA isolation kit (RNeasy, Qiagen, Chatsworth,
CA). Tissue lysis and homogenization were performed
with an automated tissue homogenizer (PowerGen 35
Homogenizer, Fisher Scientific), using disposable gener-
ator tips to prevent RNA cross contamination.
Reverse Transcription
cDNA was synthesized from 1-5 μg of total RNA using a
cDNA synthesis kit (Superscript preamplification system,
GibcoBRL, Gaithersburg, MD). The oligo-dT priming
method was utilized.
Polymerase Chain Reaction
Three CEA specific oligonucleotide primers for nested
PCR were designed from previously published
sequences.
7-
9 The primer sequences for CEA were as fol-
lows: Primer A, 5'-TCTGGAACTTCTCCTG-
GTCTCTCAGCTGG-3'; Primer B, 5'-TGTAGCTGTTG-
CAAATGCTTTAAGGAAGAAGC-3'; and Primer C, 5'-
GGGCCACTGTCGGCATCATGATTGG-3'. The nested
PCR was performed in two successive steps. Step 1 was
performed in a 20 μl reaction volume containing 1X PCR
buffer (Boehringer Mannheim), 250 μM dNTPs, 1 μM
each primers A and B, and 0.5 U Taq DNA polymerase
(Boehringer Mannheim). Twenty rounds of amplifica-
tion were performed in a thermocycler (DNA
Thermocycler 480, Perkin Elmer) under the following
cycling conditions: 95° C (1 min) denaturation, 72° C (1
Table 1.
Results of histological and RT-PCR examination of lymph nodes
from patients with esophageal carcinoma.
Case number
1
2
3
4
5
6
7
8
9
10
11
12
13
Diagnosis
Adeno
Adeno
Adeno
Adeno
Adeno
Adeno
Adeno
scc
Adeno
Adeno
Adeno
Adeno
Adeno
Positive Lymph Nodes
Histology
0/2
0/1
0/2
2/4
6/8
7/17
5/8
1/7
1/2
1/2
3/4
1/1
2/2
RT-PCR
2/2
1/1
0/2
3/4
7/8
12/17
8/8
3/7
2/2
2/2
3/4
1/1
2/2
Status/Follow-up
DWD/5 mos
DWD/2 mos
NED/12 mos
NED/11 mos
AWD/7 mos
AWD/9 mos
NED/7 mos
AWD/7 mos
AWD/20 mos
AWD/7 mos
DWD/10 mos
AWD/9 mos
NED/5 mos
Abbreviations: Adeno=esophageal adenocarcinoma; SCC=esophageal squamous cell carci-
noma; DWD=died with disease; NED=no evidence of disease; AWD=alive with disease
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min) annealing, 72° C (1 min) extension, followed by a
final extension of 72° C (10 min). Two ul of the Step 1
reaction product was transferred to another tube con-
taining primers B and C, PCR buffer, dNTPs, and Taq
DNA polymerase in the same concentrations as in Step 1.
Step 2 was also performed in a 20 μl reaction volume.
The second PCR reaction was performed under the same
conditions as Step 1. Step 1 yields a 160-bp PCR prod-
uct; the second PCR reaction produces a 131-bp product.
As a positive control for RNA quality, a PCR assay for a-
actin was performed for each sample. The primer
sequences were as follows: 5'-CCTGGCACCCAGCA-
CAATGA-3', and 5'-ACGAAGGCTCATCATTCAAA-3'. The
actin PCR was performed with 30 rounds of amplification
under the following cycling conditions: 94° C (30 sec)
denaturation, 68° C (45 sec) annealing, 72° C (1 min)
extension, followed by a 7 minute final extension at 72°
C.
To check for possible contamination with genomic DNA,
RT-PCR reactions were also performed without a reverse
transcription step.
PCR Product Analysis
PCR products were analyzed on a 1.5% agarose gel con-
taining 0.5 μg/ml ethidium bromide. A 100-bp ladder
(Boehringer Mannheim) served as a molecular weight
marker. PCR products were separated by electrophore-
sis at 80 volts for 2-3 h.
Lymph Node Samples
Informed consent was obtained from all patients as spec-
ified in University of Pittsburgh Cancer Institute protocol
94-121. Sixty lymph node samples were obtained from
13 patients with carcinoma of the esophagus. Lymph
nodes from patients with esophageal cancer were
obtained during combined laparoscopic and videothora-
coscopic staging or esophagectomy. As a control, 10
lymph nodes were obtained from 6 patients undergoing
treatment of a benign esophageal disease, such as gas-
troesophageal reflux disease or achalasia. Five lymph
nodes were evaluated from a patient with a history of
long-standing reflux and Barrett's metaplasia. In addition
to lymph nodes, 8 samples of esophageal carcinoma (7
adenocarcinoma, 1 squamous cell carcinoma), and 5
samples of normal esophagus were studied.
Each sample was carefully dissected from perinodal fat
and soft tissue and then sectioned into two pieces. One
piece was fixed and embedded in paraffin and used for
histologic analysis. The remaining piece was immedi-
ately placed in liquid nitrogen and stored at -70°C until
RNA extraction. Following the RT-PCR analysis the
results of histologic examination and RT-PCR were com-
pared.
RESULTS
Normal Esophagus and Carcinoma Samples
RT-PCR amplification of all 8 samples of esophageal car-
cinoma and 5 samples of normal esophagus demonstrat-
ed the 131-bp CEA band (Figure 1). No product was
observed in control PCR reactions performed without the
reverse transcription, demonstrating that there was no
contamination with genomic DNA (Figure 2).
Lymph Node Samples
Histologic examination detected metastases in 29 of 60
(48%) lymph node specimens studied. All histologically
positive lymph node samples demonstrated a positive
CEA signal by RT-PCR. The number of lymph node
metastases detected increased to 46 of 60 (77%) when
RT-PCR was used. Seventeen of 31 (52%) histologically
Figure 1. Occult lymph node metastases in esophageal cancer.
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Figure 2. Occult lymph node metastases in esophageal can-
cer.
negative lymph nodes were found by RT-PCR analysis to
express the mRNA for CEA by RT-PCR (Figure 3). In
three patients, all regional lymph nodes were negative
histologically. Of these patients, two demonstrated
lymph node metastases by RT-PCR and both of these
patients died of disease progression within 12 months.
The remaining patient, negative histologically and by RT-
PCR, remains without disease recurrence 12 months after
surgical resection. In nine patients, RT-PCR indicated an
increased number of metastatic lymph nodes compared
to histologic review. In three patients, histologic and RT-
PCR diagnostic methods detected the same number of
lymph node metastases (Table 1).
All lymph nodes with histologic evidence of metastases
failed to demonstrate the characteristic 131-bp band
when PCR without reverse transcription was performed,
indicating that genomic DNA contamination did not
occur. All lymph nodes from patients with benign
esophageal diseases and Barrett's esophagus were nega-
tive for CEA by RT-PCR and negative by histologic exam-
ination.
Figure 3. Occult lymph node metastases in esophageal cancer.
DISCUSSION AND CONCLUSIONS
The identification of lymph node metastasis in patients
with esophageal cancer is an important determinant of
prognosis and impacts on the clinical decision making
process.
11-1
3 Randomized trials of multimodality treat-
ment regimens have been performed but have not uni-
formly improved survival compared to surgery alone.
2 A
major drawback in these studies is that accurate pre-
treatment staging prior to the initiation of therapy was
not performed, thus limiting any meaningful evaluation
of therapeutic response. This approach of grouping
patients based only on the presence or absence of dis-
tant metastases without consideration of the extent of
locoregional disease also limits evaluation of survival
data on a stage by stage basis. Since a number of reports
have shown that not only the presence of lymph node
metastases but their number and location are important
indicators of long-term survival, it is possible that a more
accurate assessment of stage prior to treatment would
allow a more thorough evaluation of efficacy.
11-1
3
Conventional imaging modalities employed to assess
lymph node and distant metastases are inaccurate in over
40% of patients when compared to minimally invasive
surgical staging.
3,
4 Positron emission tomography offers
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a significant improvement over computerized tomogra-
phy in detecting distant metastatic disease but is only
45% sensitive in detecting metastases lymph nodes under
1 cm in diameter.
4 Endoscopic ultrasound is accurate in
assessment of the depth of tumor invasion but its utility
in detecting small lymph node metastases has been ques-
tioned.
14-1
7
Currently, the most accurate method to stage patients
with esophageal cancer is by minimally invasive surgical
biopsy. However, this approach is associated with a
small but measurable morbidity, significant expense and
requires an extensive surgical dissection to avoid sam-
pling errors and under staging. Once lymph nodes are
surgically biopsied, further errors may take place in the
histologic evaluation since up to 20% of histologically
negative lymph nodes are positive on re-examination.
5
Immunohistochemical staining of lymph nodes to detect
tumor markers may result in a higher detection rate of
micrometastases when compared to histological exami-
nation but this technique is time consuming and labor
intensive, and is not in widespread clinical use.
18-2
1
Sensitive molecular methods, such as RT-PCR, have
recently been employed to detect lymph node metas-
tases in a variety of malignancies such as malignant
melanoma, breast, colorectal, gastric, and esophageal
carcinoma.
9,22-2
5 This method is designed to detect mark-
ers expressed in the carcinoma cells but not in normal
lymph nodes. A CEA specific RT-PCR assay has been
developed to detect carcinoma cells in bone marrow
samples from patients with colorectal, pancreatic, or gas-
tric carcinoma.
8 Recently, this method has been modi-
fied to detect lymph nodes metastases in patients with
esophageal, gastric, colorectal, and breast cancer.
9 This
preliminary report included a small number of patients
with esophageal cancer.
Our preliminary experience with RT-PCR to detect the
mRNA for CEA confirms that this technique has the
potential to improve the accuracy of detecting lymph
node metastases in esophageal cancer compared to his-
tologic evaluation. As expected, CEA was present in all
samples of esophageal carcinoma and normal esophagus
and thus appears to be a marker specific for epithelial
cells. Importantly, CEA was not present in any of the
lymph nodes from patients without cancer. Thus in the
absence of cancer there is no migration of epithelial cells
from the esophagus to the lymph nodes. Histologic
assessment of lymph nodes from patients with
esophageal cancer detected 29 of 60 lymph nodes
involved with metastatic disease. All histologically posi-
tive lymph nodes were positive by RT-PCR for CEA, indi-
cating that there were no false negative results using this
method. The number of positive lymph nodes increased
to 49 of 60 when RT-PCR technology was applied. Two
of three patients with histologically negative lymph
nodes were determined to have nodal disease by RT-PCR
staging. In nine of the 13 patients with esophageal can-
cer, the number of positive lymph nodes detected was
increased by RT-PCR compared to histology.
CEA-specific RT-PCR is an extremely sensitive technique
that facilitates the detection of histologically occult lymph
node metastases in patients with esophageal cancer. The
technique has the potential to improve upon the accura-
cy of current staging, aid in the evaluation of response to
treatment, and impact on clinical decision making in
patients with esophageal cancer. Further studies with
clinical follow-up will be required to evaluate the role of
RT-PCR in the diagnosis and treatment of patients with
esophageal cancer.
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